What InTest Holders Bought Into
If you only skimmed the early 2025 debate on InTest, with one camp focused on Malaysia-driven upside and another warning about soft orders and trade risk, you might not have expected what actually happened. For InTest shareholders, the return over the past year was 58.2%, including dividends. If you had been weighing those opposing views on 23 October 2025, which parts of the business story would you have trusted most?
This theme extends beyond InTest. See which of 95 robotics and automation stocks may still merit a closer look.
The Two InTest Stories Investors Were Arguing About
The shares cost US$8.72 at the start of the period, and anyone looking at InTest back then was being asked to choose between two very different futures built on the same set of facts.
On the optimistic side, the bullish narrative put Fair Value at US$12, the price implied if the Malaysia facility and Alfamation acquisition really did unlock extra regional revenue, diversify end markets, and support a move toward higher profit margins over time.
The more cautious view set Fair Value at US$8 and stressed that soft semiconductor orders, customer concentration, and geopolitical risk around that same Malaysian build out could leave revenue growth and earnings under pressure for longer than bulls expected.
What The Results Changed For The InTest Debate
The clearest new fact for InTest was management lifting its full year 2026 revenue outlook to US$130 million to US$135 million after first quarter outperformance and better semiconductor demand, which leaned toward the optimistic Malaysia and diversification story. Reported results added weight, with revenue at US$35.313 million and net income at US$0.474 million in Q2 2026 and a 1.3% margin, so profitability remained early and modest. Overall, the evidence cut both ways.
The key lesson is simple. When a thesis leans on new capacity and acquisitions, treat upgraded revenue targets and the shift from losses to profit as the main claims to check in later filings, not the share price move.
What InTest's Run Up 58% Still Leaves You Paying For
InTest now trades at US$13.75, and the selected Narrative places Fair Value above that level, tying the gap to how far diversification and product mix improvements can carry margins.
The Narrative argues the current price still does not fully credit consistent execution on non semiconductor expansion and the follow through from recent semiconductor order strength.
"The main factor that has to go right is continued execution on diversification into Auto/EV, Defense/Aerospace, Industrial and Life Sciences, alongside footprint and cost efficiencies so that higher revenue translates into stronger and more consistent margins."
That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for
How Could You Get There Earlier?
By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.
- Company 1 - 40% below our estimate - use government-backed trade-in programs to drive higher margin refurbishment volumes.
- Company 2 - 28% below our estimate - supply testing equipment utilities and defense contractors need for modernized infrastructure.
- Company 3 - 33% below our estimate - target AI data center hardware budgets where chips and software stay tightly linked.
Those are three of them. See every one of the 27 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com